PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33798839-8	2021	Metformin significantly decreased the release of anti-angiogenic factors sFlt-1 and sEng from ex-vivo placental and umbilical vein tissue, and increased maternal serum levels of non-phosphorylated IGFBP-1.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	197-204	
32652973-0	2020	Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	93-114	
32652973-2	2020	We studied whether metformin treatment has favorable or unfavorable effects on inflammatory markers and insulin-like growth factor-binding protein 1 (IGFBP-1) in GDM patients compared with insulin, and whether these markers associate with major maternal or fetal clinical outcomes.	Metformin	19-28	insulin like growth factor binding protein 1	Homo sapiens	104-148	
32652973-2	2020	We studied whether metformin treatment has favorable or unfavorable effects on inflammatory markers and insulin-like growth factor-binding protein 1 (IGFBP-1) in GDM patients compared with insulin, and whether these markers associate with major maternal or fetal clinical outcomes.	Metformin	19-28	insulin like growth factor binding protein 1	Homo sapiens	150-157	
32652973-7	2020	GlycA (p = 0.02) and non-phosphorylated IGFBP-1 (p = 0.008) increased more in patients treated with metformin than those treated with insulin.	Metformin	100-109	insulin like growth factor binding protein 1	Homo sapiens	40-47	
32652973-9	2020	CONCLUSIONS: Metformin had beneficial effects on maternal serum IGFBP-1 concentrations compared to insulin, as increased IGFBP-1 related to lower total and late pregnancy maternal weight gain.	Metformin	13-22	insulin like growth factor binding protein 1	Homo sapiens	64-71	
25687657-1	2015	PURPOSE: To assess the metformin effect on endometrial stromal cell decidualization, proliferation, gene and protein expression of IGFBPs, IGFs and their receptors.	Metformin	23-32	insulin like growth factor binding protein 1	Homo sapiens	131-137	
31628524-8	2019	Metformin effectively inhibited the increase of IGF-1 and maintained the IGFBP-1.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	73-80	
29073599-0	2017	Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression Through Inactivation of Stat3 and Reciprocal Interaction Between FOXO3a and SP1.	Metformin	31-40	insulin like growth factor binding protein 1	Homo sapiens	53-59	
25687657-9	2015	Higher concentrations of metformin lead to a significant (p < 0.05) dose-dependent attenuation of the progesterone effect with regard to IGFBP-1, -3, -5, -6, as well as IGF I receptor, while it did not change the expression of IGFBP-2 and -4, IGF I and II and the IGF II receptor.	Metformin	25-34	insulin like growth factor binding protein 1	Homo sapiens	140-159	
21316309-0	2011	Metformin modulates IL-8, IL-1beta, ICAM and IGFBP-1 expression in human endometrial stromal cells.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	45-52	
25253174-7	2014	Compared with placebo, metformin significantly decreased ki-67 in women with HOMA > 2.8, those in the lowest IGFBP-1 quintile, those in the highest IGFBP-3 quartile, those with low free IGF-I, those in the top hs-CRP tertile, and those with HER2-positive tumors.	Metformin	23-32	insulin like growth factor binding protein 1	Homo sapiens	112-119	
25289085-7	2014	Metformin was observed to downregulate IGF-1R and upregulate IGF binding protein-1 (IGFBP-1) mRNA and protein expression, while compound C, an adenosine monophosphate protein kinase inhibitor, reversed this effect.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	61-82	
25289085-7	2014	Metformin was observed to downregulate IGF-1R and upregulate IGF binding protein-1 (IGFBP-1) mRNA and protein expression, while compound C, an adenosine monophosphate protein kinase inhibitor, reversed this effect.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	84-91	
21316309-6	2011	IGFBP-1 gene expression was reduced after long-term metformin exposure (7.7 fold, P<0.05).	Metformin	52-61	insulin like growth factor binding protein 1	Homo sapiens	0-7	
16492692-9	2006	Metformin was also associated with lower insulin resistance and leptin and IGF-I levels and higher SHBG and IGF-binding protein-1 levels and with a more favorable lipid profile.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	108-129	
17350746-0	2008	Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome.	Metformin	10-19	insulin like growth factor binding protein 1	Homo sapiens	33-40	
29699342-10	2010	Treatment with an insulin-sensitizing agent (metformin) improves the levels of glycodelin, insulin-like growth factor binding protein 1, and blood flow in spiral arteries during the peri-implantation period.	Metformin	45-54	insulin like growth factor binding protein 1	Homo sapiens	91-135	
15063962-10	2004	CONCLUSIONS: The present study shows that metformin therapy not only restores normal levels of insulin and testosterone, but also decreases the pool of free-bioactive IGF-I by increasing the levels of circulating IGFBP-1.	Metformin	42-51	insulin like growth factor binding protein 1	Homo sapiens	213-220	
11239532-11	2001	Metformin led to modulation of preovulatory of follicular fluid IGF levels with increases of IGF-I (140 +/- 8 vs. 109 +/- 7ng/mL) and decreased of IGFBP-1 (133 +/- 8 vs.153 +/- 9ng/mL).	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	147-154	
15063962-2	2004	This study was designed to evaluate effects of metformin therapy on serum levels of IGFBP-1 and IGF-I.	Metformin	47-56	insulin like growth factor binding protein 1	Homo sapiens	84-91	
15063962-6	2004	RESULTS: Metformin therapy significantly increased IGFBP-1 concentration by 38% (P = 0.05) but had no demonstrable effect on the total IGF-I levels.	Metformin	9-18	insulin like growth factor binding protein 1	Homo sapiens	51-58	
11238496-0	2001	Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.	Metformin	23-32	insulin like growth factor binding protein 1	Homo sapiens	77-121	
11238496-11	2001	We conclude that insulin reduction with metformin increases follicular and luteal phase serum glycodelin and insulin-like growth factor-binding protein-1 concentrations and enhances luteal phase uterine vascularity and blood flow in the polycystic ovary syndrome.	Metformin	40-49	insulin like growth factor binding protein 1	Homo sapiens	109-153